Trial Profile
Effects of piperacillin-tazobactam use on the prevalence rate of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Escherichia coli infections; Gram-positive infections; Klebsiella infections
- Focus Therapeutic Use
- Sponsors Wyeth
- 16 Mar 2007 New trial record.